“Overprescribing among older people near end of life in Ireland: Evidence of prevalence and determinants from The Irish Longitudinal Study on Ageing (TILDA),” by Soraya Matthews, Frank Moriarty, Mark Ward, Anne Nolan, Charles Normand, Rose Anne Kenny, and Peter May (PLoS ONE 17(9): e0273948. doi.org/10.1371/journal.pone.0273948, XML, HTML, and .pdf format, 15p.).
journals.plos.org/plosone/article?id=10.1371/journal.pone.0273948
“Drug use among seniors in Canada,” (October 2022, HTML and Excel format).
“Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019,” by Stacie B. Dusetzina, Haiden A. Huskamp, Xuanzi Qin, and Nancy L. Keating (Vol. 328, No. 15, October 18, 2022, p. 1515-1522).
“Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2020 Average Sales Prices,” (OEI-03-22-00170, September 2022, .pdf format, 7p.).
“How Will the Prescription Drug Provisions in the Inflation Reduction Act Affect Medicare Beneficiaries?” by Juliette Cubanski, Tricia Neuman, Meredith Freed, and Anthony Damico (August 2022, HTML and .pdf format, 8p.).
“Lowering Health Care Costs for Nevada Seniors: Taking Action to Bring Down Prescription Drug Prices,” a hearing held August 23, 2022 (witness statements available in .pdf format, video of the full hearing available at the site, running time 1 hour 35 minutes). Note: Hearing begins at the 15:05 mark.
“Utilization Management for Prescription Drugs Commonly Used by Older Adults: Wide State Variation Among Top Marketplace Plans,” by James McSpadden (August 2022, .pdf format, 5p.).
www.aarp.org/ppi/info-2022/utilization-management-for-prescription-drugs.html
“Part D Plan Preference for Higher-Cost Hepatitis C Drugs Led to Higher Medicare and Beneficiary Spending,” (OEI-BL-21-00200, August 2022, .pdf format, 35p.).
“How Would the Prescription Drug Provisions in the Senate Reconciliation Proposal Affect Medicare Beneficiaries?” by Juliette Cubanski, Tricia Neuman, Meredith Freed, and Anthony Damico (July 2022, .pdf and HTML format, 8p.).
“Affordable Prescriptions Now: Examining Legislation to Lower Costs for Seniors,” a hearing held July 1, 2022 (witness statements available in .pdf format, video of the full hearing available at the site, running time 2 hours 18 minutes). Note: Hearing begins aa the 31:33 mark.
“Potentially Inappropriate Medication Prescribed to Seniors,” (May 2022, Excel format).
www.cihi.ca/en/indicators/potentially-inappropriate-medication-prescribed-to-seniors
“Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients,” by Kin Wah Fung, Seo H. Baik, Fitsum Baye, Zhaonian Zheng, Vojtech Huser, and Clement J. McDonald (PLoS ONE 17(4): e0266922. doi.org/10.1371/journal.pone.0266922, XML, HTML, and .pdf format, 15p.).
journals.plos.org/plosone/article?id=10.1371/journal.pone.0266922
“No Time to Wait: Proposals to Lower Prescription Drug Costs,” a hearing held April 12, 2022 (witness statements available in .pdf format, video of the full hearing available at the site, running time 1 hour 6 minutes). Note: Hearing begins at the 13:00 mark.
www.aging.senate.gov/hearings/no-time-to-wait-proposals-to-lower-prescription-drug-costs
A. “Over 9 Million Adults Ages 50 and Older Faced Food Insecurity in 2020,” by Olivia Dean and Carlos Figueiredo (March 2022, .pdf format, 6p.).
www.aarp.org/ppi/info-2022/food-insecurity-adults-50-and-older.html
B. “Trends in Utilization Management of Prescription Drugs in Top Marketplace Plans,” by James McSpadden (April 2022, .pdf format, 6p.).
www.aarp.org/ppi/info-2022/trends-utilization-management-top-drug-plans.html%20/
“2023 Medicare Advantage rate book and Prescription Drug rate information,” (March 2022, zipped comma-delimited and Excel format).
www.cms.gov/medicarehealth-plansmedicareadvtgspecratestatsratebooks-and-supporting-data/2023
“Medicare Part D and Beneficiaries Could Realize Significant Spending Reductions With Increased Biosimilar Use,” (OEI-05-20-00480, March 2022, .pdf format, 33p.).
“Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare,” a hearing held March 16, 2022 (witness statements available in .pdf format, video of the full hearing available at the site, running time 2 hours 44 minutes). Note: The hearing begins at the 20:49 mark.
“Prices Increased Faster Than Inflation for Half of all Drugs Covered by Medicare in 2020,” by Juliette Cubanski and Tricia Neuman (February 2022, .pdf and HTML format, 8p.).
A. “The Prices That Commercial Health Insurers and Medicare Pay for Hospitals’ and Physicians’ Services,” (January 2022, .pdf and HTML format, 45p.).
B. “Prescription Drugs: Spending, Use, and Prices,” (January 2022, .pdf and HTML format, 23p.).
“Simulating the Impact of the Drug Price Negotiation Proposal in the Build Back Better Act,” by Juliette Cubanski, Nolan Sroczynski, and Tricia Neuman (January 2022, .pdf and HTML format, 8p.).
“Medication Literacy: A Helpful Concept for Understanding Medication Decision Making among Older Adults,” by James McSpadden (January 2022, .pdf format, 7p.).
“CMS Should Strengthen Its Prescription Drug Event Guidance To Clarify Reporting of Sponsor Margin for Medicare Part D Bids,” (A-03-17-00001, November 2021, .pdf format, 15p.).
“Explaining the Prescription Drug Provisions in the Build Back Better Act,” by Juliette Cubanski, Tricia Neuman, and Meredith Freed (November 2021, .pdf and HTML format, 14p.).
“Brand-Name Drug Prices: The Key Driver of High Pharmaceutical Spending in the U.S.: An International Comparison of Prescription Drug Spending and Costs,” by Aimee Cicchiello and Lovisa Gustafsson (November 2021, HTML, .pdf, and Powerpoint format, 11p.).
“Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans, 2006 to 2020,” by Leigh Purvis and Dr. Stephen Schondelmeyer (September 2021, .pdf format, 30p.).
www.aarp.org/ppi/info-2019/trends-in-retail-prices-of-drugs.html
“How Would Drug Price Negotiation Affect Medicare Part D Premiums?” by Juliette Cubanski and Tricia Neuman (August 2021, .pdf and HTML format, 3p.).
www.kff.org/medicare/issue-brief/how-would-drug-price-negotiation-affect-medicare-part-d-premiums/
“Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016,” by Eric H. Young, Samantha Pan, Alex G. Yap, Kelly R. Reveles, and Kajal Bhakta (PLoS ONE 16(8): e0255642. doi.org/10.1371/journal.pone.0255642, XML, HTML, and .pdf format, 10p.).
journals.plos.org/plosone/article?id=10.1371/journal.pone.0255642
“Novel Anticoagulants Achieve Rapid Market Penetration despite Higher Costs,” by Catherine W. Gillespie and Leigh Purvis (June 2021, .pdf format, 7p.).
A. “Drug Price Increases That Exceed Inflation Are Costing Medicare Part D Billions,” by Leigh Purvis (June 2021, .pdf format, 5p.).
www.aarp.org/ppi/info-2021/drug-price-increases-that-exceed-inflation-are-costing-medicare.html
B. “Rx Price Watch Report: Trends in Retail Prices of Brand Name Prescription Drugs Widely Used by Older Americans, 2006 to 2020,” by Leigh Purvis and Dr. Stephen Schondelmeyer (June 2021, .pdf format, p.).
www.aarp.org/ppi/info-2019/trends-in-retail-prices-of-drugs.html
“Negotiating a Better Deal: Legislation to Lower the Cost of Prescription Drugs,” a hearing held May 4, 2021 (witness statements available in .pdf format, video of the full hearing available at the site, running time 4 hours 11 minutes). Note: The hearing begins at the 10:58 mark.
“Prescription Drugs: U.S. Prices for Selected Brand Drugs Were Higher on Average than Prices in Australia, Canada, and France,” (GAO-21-282, March 2021, .pdf format, 65p.).
“Relatively Few Drugs Account for a Large Share of Medicare Prescription Drug Spending,” by Juliette Cubanski and Tricia Neuman (April 2021, HTML format).
“A Comparison of Brand-Name Drug Prices Among Selected Federal Programs,” (February 2021, HTML and .pdf format, 34p.).
“CBO’s Model of Drug Price Negotiations Under the Elijah E. Cummings Lower Drug Costs Now Act,” by Christopher Adams and Evan Herrnstadt (Working Paper 2021-01, February 2021, .pdf format, 28p.). Note: A link to the abstract and the full-text of this paper is available at:
“Price Increases Continue to Outpace Inflation for Many Medicare Part D Drugs,” by Juliette Cubanski and Tricia Neuman (February 2021, HTML format).
A. “Association of low back pain with muscle weakness, decreased mobility function, and malnutrition in older women: A cross-sectional study,” by Satoshi Kato, Satoru Demura, Kazuya Shinmura, Noriaki Yokogawa, Tamon Kabata, Hidenori Matsubara, Yoshitomo Kajino, Kentaro Igarashi, Daisuke Inoue, Yuki Kurokawa, Norihiro Oku, and Hiroyuki Tsuchiya (PLoS ONE 16(1): e0245879. doi.org/10.1371/journal.pone.0245879, HTML, XML, and .pdf format, 11p.).
journals.plos.org/plosone/article?id=10.1371/journal.pone.0245879
B. “Adipocyte-induced transdifferentiation of osteoblasts and its potential role in age-related bone loss,” by Aline Clabaut, Céline Grare, Gaëlle Rolland-Valognes, Jean-Guillaume Letarouilly, Chantal Bourrier, Thomas L. Andersen, Tanja Sikjær, Lars Rejnmark, Charlotte Ejersted, Philippe Pastoureau, Pierre Hardouin, Massimo Sabatini, and Odile Broux (PLoS ONE 16(1): e0245014. doi.org/10.1371/journal.pone.0245014, HTML, XML, and .pdf format, 17p.).
journals.plos.org/plosone/article?id=10.1371/journal.pone.0245014
C. “Identification of drug combinations on the basis of machine learning to maximize anti-aging effects,” by Sun Kyung Kim, Peter C. Goughnour, Eui Jin Lee, Myeong Hyun Kim, Hee Jin Chae, Gwang Yeul Yun, Yi Rang Kim, and Jin Woo Choi (PLoS ONE 16(1): e0246106. doi.org/10.1371/journal.pone.0246106, XML, HTML, and .pdf format, 19p.).
journals.plos.org/plosone/article?id=10.1371/journal.pone.0246106
“Prescription Drugs: Department of Veterans Affairs Paid About Half as Much as Medicare Part D for Selected Drugs in 2017,” (GAO-21-111, December 2020, .pdf format, 23p.).
“Out-of-Pocket Spending for Retail Prescribed Drugs by Age and Type of Prescription Drug Coverage, 2009 to 2018,” by William A. Carroll, G. Edward Carroll, and Steven C. Hill (Medical Expenditure Panel Survey Statistical Brief No. 532, December 2020, .pdf and HTML format, 11p.).
meps.ahrq.gov/mepsweb/data_stats/Pub_ProdResults_Details.jsp?pt=Statistical+Brief&opt=2&id=1271
“Medicare Part D: A First Look at Medicare Prescription Drug Plans in 2021,” by Juliette Cubanski and Anthony Damico (October 2020, HTML format).
“Mail Delays Could Affect Mail-Order Prescriptions for Millions of Medicare Part D and Large Employer Plan Enrollees,” by Juliette Cubanski, Jeannie Fuglesten Biniek, Matthew Rae, Anthony Damico, Brittni Frederiksen, and Alina Salganicoff (August 2020, HTML format).
“Loophole in Drug Payment Rule Continues To Cost Medicare and Beneficiaries Hundreds of Millions of Dollars,” (OEI-BL-20-00100, July 2020, .pdf format, 16p.).
“Preventing Drug Diversion: Disposal of Controlled Substances in Home Hospice Settings,” (GAO-20-378, April 2020, .pdf format, 21p.).
“The Elijah E. Cummings Lower Drug Costs Now Act: How It Would Work, How It Would Affect Prices, and What the Challenges Are,” by Paul B. Ginsburg and Steven M. Lieberman (April 2020, .pdf and HTML format, 8p.).
“Examining Current Medicare Part D Policies for Extended Supplies of Medication,” by Juliette Cubanski, Karyn Schwartz, and Anthony Damico (March 2020, HTML format).
“A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries,” by Meredith Freed, Juliette Cubanski, and Tricia Neuman (November 2019, .pdf and HTML format, 27p.).
“Assessing Drug Price Increases in Medicare Part D and the Implications of Inflation Limits,” by Juliette Cubanski and Tricia Neuman (October 2019, .pdf format, 6p.).
“Key Provisions of Proposals on Drug Price Negotiation, Inflation Rebates, and Medicare Part D Redesign,” (September 2019, .pdf and HTML format, 2p.).
“Making Prescription Drugs More Affordable: Legislation to Negotiate a Better Deal for Americans,” a hearing held September 25, 2019 (witness statements available in .pdf format, video available at the site, running time 4 hours 23 minutes). Note: Hearing starts at the 10:15 mark.
“Medicare Part D’s Effect on Evergreening, Generics, and Drug Prices,” by Geoffrey T. Sanzenbacher and Gal Wettstein (IB No. 19-14, September 2019, .pdf and Excel format, 7p.).
crr.bc.edu/briefs/medicare-part-ds-effect-on-evergreening-generics-and-drug-prices/
“Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans, 2017 Year-End Update,” by Leigh Purvis and Dr. Stephen Schondelmeyer (September 2019, .pdf format, 17p.).
www.aarp.org/ppi/info-2019/trends-in-retail-prices-of-drugs.html
Powered by WordPress
